Anavex rises after schizophrenia drug meets main goal in study

Anavex Life Sciences

02/10/2025 13:59

** Shares of Anavex Life Sciences AVXL.O rise 5.4% to $9.5 premarket

** Company says its experimental schizophrenia drug was shown to be safe and well-tolerated, meeting the main goal in a mid-stage study

** The drug, ANAVEX3-71, aims to treat adults with schizophrenia who are on stable antipsychotic medication -AVXL

** Company says ANAVEX3-71 is designed to treat symptoms associated with the mental health disorder without the side effects of standard of care antipsychotics.

** Schizophrenia is a mental disorder characterized by disruptions in thought processes, emotional responsiveness, and social interactions, causing hallucinations, delusions and impaired thinking

** As of last close, stock had fallen ~16% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Mariam.ESunny@thomsonreuters.com;))